Cytokinetics Inc
aficamten
obstructive hypertrophic cardiomyopathy
Countdown
130days
FDA decision · Nov 14, 2026
What's at stake
The FDA's approval decision on aficamten for obstructive hypertrophic cardiomyopathy is due Nov 14, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“The Supplemental New Drug Application for MAPLE-HCM was accepted for filing by the U.S. Food and Drug Administration (FDA) with a PDUFA date of November 14, 2026.”